Zacks Investment Research lowered shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) from a buy rating to a hold rating in a report released on Wednesday morning.

According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “

Separately, Canaccord Genuity restated a buy rating and set a $18.00 target price on shares of Mast Therapeutics in a research report on Monday, July 17th.

Shares of Mast Therapeutics (SVRA) opened at 5.30 on Wednesday. Mast Therapeutics has a 52 week low of $4.60 and a 52 week high of $9.88. The firm’s market cap is $73.18 million. The company has a 50 day moving average of $5.78 and a 200 day moving average of $5.89.

TRADEMARK VIOLATION WARNING: “Mast Therapeutics, Inc. (SVRA) Lowered to Hold at Zacks Investment Research” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/27/mast-therapeutics-inc-svra-lowered-to-hold-at-zacks-investment-research.html.

In related news, Director Joseph S. Mccracken bought 52,250 shares of the firm’s stock in a transaction dated Wednesday, June 7th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $248,187.50. Following the transaction, the director now owns 59,866 shares of the company’s stock, valued at $284,363.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jaakko Taneli Jouhikainen bought 10,500 shares of the firm’s stock in a transaction dated Wednesday, June 7th. The shares were bought at an average price of $4.75 per share, with a total value of $49,875.00. Following the completion of the transaction, the insider now directly owns 235,326 shares in the company, valued at approximately $1,117,798.50. The disclosure for this purchase can be found here. Insiders have bought a total of 64,850 shares of company stock valued at $308,038 over the last 90 days. Corporate insiders own 4.26% of the company’s stock.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Get a free copy of the Zacks research report on Mast Therapeutics (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related stocks with our FREE daily email newsletter.